Merck Shares Climb on 2026 Outlook, Signaling Investor Confidence in Long-Term Oncology Strategy
Merck & Co. reported solid Q4 2025 results but issued a cautious 2026 sales forecast, citing acquisition costs and patent expirations. Despite this, shares rose as the market focused on the company's sustained dividend and aggressive reinvestment in its oncology and vaccine pipelines.